SCHEMBL17633772

SCHEMBL17633772

FC(F)(F)c1ccc(C2CNc3cc(Cl)ccc3O2)cc1

nearest known ligand 0.37

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.37
SLC6A4 P31645 2/20 0.36
CSF1R P07333 1/20 0.35
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34
KMT2A Q03164 1/20 0.34
HTR2C P28335 3/20 0.34
ADAMTS5 Q9UNA0 2/20 0.34
MGLL Q99685 1/20 0.33
HTR2B P41595 1/20 0.33
HCRTR2 O43614 1/20 0.33
PARP1 P09874 1/20 0.33
PARP2 Q9UGN5 1/20 0.33
PGR P06401 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17633748 0.90 SLC6A4 (0.36) CYP2C9SLC6A4CSF1RKDM4EMEN1
SCHEMBL17633658 0.85 MAOB (0.38) CSF1RKDM4EMEN1GAAMAPT
SCHEMBL17633641 0.84 CSF1R (0.35) CSF1RKDM4EMEN1GAAMAPT
SCHEMBL4971664 0.82 ADAMTS5 (0.42) KDM4EMEN1GAAMAPTKMT2A
SCHEMBL17634138 0.81 MAOB (0.41) MEN1KMT2A
SCHEMBL17634093 0.81 ABL1 (0.36) CSF1RKDM4EMEN1GAAMAPT
SCHEMBL17634131 0.81 NISCH (0.49) KDM4EMEN1GAAMAPTKMT2A
SCHEMBL17633636 0.77 MAOB (0.41) KDM4EMEN1GAAMAPTKMT2A
SCHEMBL17633723 0.76 MEN1 (0.34) CSF1RKDM4EMEN1GAAMAPT
SCHEMBL17633717 0.74 MEN1 (0.40) KDM4EMEN1GAAMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3197900-B1 INHIBITORS OF HIF PROLYL HYDROXYLASE MERCK SHARP & DOHME (US) 2020-02-12 EP disclosed
US-9969752-B2 Inhibitors of HIF prolyl hydroxylase MERCK SHARP & DOHME CORP. (US) 2018-05-15 US disclosed
US-20170233412-A1 INHIBITORS OF HIF PROLYL HYDROXYLASE MERCK SHARP & DOHME CORP. (US) 2017-08-17 US disclosed
EP-3197900-A1 INHIBITORS OF HIF PROLYL HYDROXYLASE Merck Sharp & Dohme Corp. (US) 2017-08-02 EP disclosed
WO-2016045127-A1 INHIBITORS OF HIF PROLYL HYDROXYLASE MERCK SHARP & DOHME CORP. (US) 2016-03-31 WO disclosed
WO-2016049099-A1 INHIBITORS OF HIF PROLYL HYDROXYLASE MERCK SHARP & DOHME CORP. (US) 2016-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170233412-A1 INHIBITORS OF HIF PROLYL HYDROXYLASE HIF1AN, HIF1A, EGLN2 CYP2C9 2091/4885SLC6A4 4139/4885CSF1R 255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.